Dr Reddy’s to introduce Sanofi’s novel drug in India

Dr Reddy’s Laboratories on Monday said it has expanded its partnership with Sanofi Healthcare to introduce a novel drug for the prevention of lower respiratory tract disease in newborns.

The company plans to introduce Beyfortus, which contains the monoclonal antibody nirsevimab, in a prefilled injection used for the prevention of



respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in newborns and infants.

The medication is also administered in children up to 24 months of age, who remain vulnerable to severe RSV disease through their second RSV season. RSV is a highly contagious virus that can lead to serious respiratory illness in infants.